Merck & Co. (NYSE:MRK), the pharmaceutical giant behind cancer drug Keytruda and a broad portfolio of vaccines and therapeutics, is facing fresh political scrutiny after a bipartisan group of U.S. lawmakers opened national security inquiries into its clinical trial operations in China. The stock closed at 128.5 dollars, down 0.68% on the day, as investors weighed the headline risk against an otherwise resilient earnings profile.
At a Glance
- Price: 128.5 USD, down 0.68% on the day
- 52-week range: 107.9 to 130.29 USD
- Market cap: 317.77 billion USD
- P/E ratio: 35.99
- Dividend yield: 2.65%
- RSI: 68.01
| Price | 128.5 USD |
|---|---|
| Day change | -0.88 (-0.68%) |
| 52-week range | 107.9 – 130.29 |
| Market cap | $317.77B |
| P/E ratio | 35.99 |
| EPS (ttm) | 3.57 |
| Dividend yield | 2.65% |
| RSI (14) | 68.01 |
| Volume | 11,837,218 |
Congressional Letters Target Trial Practices in Xinjiang
Letters dated Monday, led by Republican Representative John Moolenaar of Michigan in his role as chair of the House Select Committee on the Chinese Communist Party, asked Merck and AbbVie to turn over documentation by July 17 covering due diligence procedures, data protection standards and oversight at clinical trial sites across China. The committee singled out sites in the Xinjiang region and at military hospitals as areas of particular concern, according to letters reviewed by Reuters and first reported this week.
The correspondence draws a direct line between the trial sites and Xinjiang's status as what the lawmakers describe as the center of Beijing's campaign against Uyghurs and other ethnic and religious minorities. It cites documentation from Chinese researchers themselves pointing to lapses in securing informed consent from participants in some studies. The letters also reference the Uyghur Forced Labor Prevention Act of 2021, noting that while the law does not directly regulate clinical trials, its underlying principles are relevant given the ethical exposure of operating in the region.
Merck responded that patient safety and ethical integrity remain central to its clinical research program and said the company adheres to global regulatory guidelines wherever trials are conducted. AbbVie declined to comment on the letters. A spokesperson for China's embassy in Washington dismissed the committee's actions as lacking credibility and accused U.S. lawmakers of politicizing trade and technology matters.
Why China Has Become a Trial Hub
The letters frame China's rise as a clinical trial destination in blunt terms, describing a combination of regulatory reform, state subsidies and what the lawmakers call questionable ethical standards that together made the country the fastest and cheapest place in the world to run early-stage human drug trials. The shift in global trial share backs up that framing: the U.S. portion of global early drug development programs fell to roughly 37% by 2024 from about 48% in 2015, while China's share climbed to over 32% from just 8% over the same period, based on industry research cited in the letters.
That reallocation of trial volume has drawn attention beyond this single case. A December report from the National Security Commission on Emerging Biotechnology warned that China has built a vertically integrated biotechnology ecosystem positioned to challenge U.S. leadership in the sector. The Merck and AbbVie inquiries fit into that broader pattern of congressional concern over how deeply American drugmakers have embedded their research and development pipelines into Chinese infrastructure.
Notably, the letters sent to AbbVie chief executive Robert Michael and Merck chief executive Robert Davis stop short of alleging wrongdoing. They state plainly that there is no evidence either company engaged in illegal activity, framing the issue instead as one of exposure: conducting trials in China, the lawmakers argue, inherently carries ethical and security risks that warrant closer examination regardless of whether any violation has occurred.
What the Numbers Say
Merck's valuation sits at a P/E of 35.99, a multiple that reflects investor willingness to pay up for the company's oncology franchise and pipeline depth even as this latest political controversy adds a layer of uncertainty. That multiple is elevated relative to the broader pharmaceutical sector average, suggesting the market has already priced in continued growth from Keytruda and successor therapies rather than treating the stock as a value play.
Momentum readings point toward a stock that has run hot. An RSI of 68.01 sits just below the conventional overbought threshold of 70, indicating buying pressure has been persistent even as shares trade near the top of their 52-week range of 107.9 to 130.29 dollars. The current price of 128.5 dollars places Merck within roughly 1.4% of its 52-week high, a position that typically invites profit-taking or consolidation, particularly when a stock encounters an unrelated news catalyst like a congressional inquiry.
Income-focused investors have another data point to weigh: a dividend yield of 2.65%, which remains a core part of Merck's appeal to holders who prioritize cash return alongside growth. That yield, combined with the company's market capitalization of 317.77 billion dollars, keeps Merck firmly in large-cap pharmaceutical territory where dividend consistency has historically mattered more than in smaller, growth-only biotech names.
The bull case rests on Merck's underlying commercial momentum, a still-strong RSI suggesting the market has not soured on the stock despite the daily dip, and a dividend that provides a floor of sorts for long-term holders. The bear case centers on regulatory and reputational risk: a formal congressional investigation, even one that has not alleged specific wrongdoing, can prompt scrutiny of overseas trial data, invite delays in regulatory review, or draw further political attention to Merck's operations in a geopolitically sensitive region. A P/E near 36 also leaves less room for error if sentiment shifts, since the stock is priced for continued execution rather than for absorbing an unexpected setback.
Frequently Asked Questions
What exactly are lawmakers investigating?
The House Select Committee on the Chinese Communist Party, led by Representative John Moolenaar, has asked Merck and AbbVie to provide details on due diligence, data protection and ethical standards at clinical trial sites in China, with particular focus on Xinjiang and military hospitals, by July 17.
Has Merck been accused of breaking any laws?
No. The letters explicitly state there is no evidence that Merck or AbbVie engaged in illegal activity or wrongdoing; the concern raised is that operating trials in China exposes the companies to ethical and security risks.
Why has China become such a large hub for clinical trials?
Industry data cited in the congressional letters shows China's share of global early drug development programs rose from about 8% in 2015 to over 32% by 2024, driven by regulatory reforms, state subsidies and lower operating costs compared with the U.S. and other markets.
How has Merck stock reacted to the news?
Merck shares closed at 128.5 dollars, down 0.68% on the day the letters became public, a modest move that keeps the stock near the upper end of its 52-week range of 107.9 to 130.29 dollars.
Watching for the July 17 Response
The next concrete milestone is the July 17 deadline lawmakers have set for Merck and AbbVie to respond with documentation. How thoroughly the companies address questions about informed consent practices and site oversight in Xinjiang will likely shape whether this inquiry escalates into broader regulatory action or fades as a contained political episode. For a stock trading near record highs with a rich valuation, the market's tolerance for added uncertainty may be thinner than usual.
